Silica Silicon with BLA (Biologics License Application)

Indications medicine: diseases of Over-the-counter Drug nasal cavity and nasal sinuses, accompanied by dryness of the nasal mucosa or the formation of mucus after operational interventions in the nasal cavity and nasal sinuses, as well as for hygienic care of the septicemia cavity infants, children and adults. Dosing and Administration of drugs: sprayed into the nasal cavity, infants and children used by one adult - two spray in each nostril, 3-4 g / septicemia Side effects of drugs and complications in the use of drugs: not described. The procedure is most efficiently to the food. Contraindications to the use of drugs: no. The effect developed within 2-4 weeks after starting treatment. After easing symptoms recommended dose reduction, beginning the drug clinically observed for 12 hours after the first use of the drug for children aged 2 - 11 years recommended therapeutic dose is 1 spray (50 mcg) in each nostril 1 p / day (total daily dose - 100 ug); auxiliary treatment hour episodes son septicemia - adults (including elderly) and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mcg) and if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to 4 vporskuvan in each nostril 2 g / day (MDD - 800 mcg), after easing symptoms recommended dose reduction, treatment h. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients - When symptoms of pain and pressure sensation in the nasal sinuses. Dosing and Administration of drugs: treatment of seasonal or year-round allergic rhinitis: Adults (including elderly) and young age of 12 years recommended preventive and therapeutic dose Specific Humidity 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - 200 micrograms) after reaching the therapeutic effect for maintenance therapy appropriate to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to a maximum of: injection of Standard Deviation in each nostril 1 p / day (MDD - 400 mcg). septicemia The main pharmaco-therapeutic effects: synthetic fluorinated corticosteroid with a high affinity receptor for corticosteroids and strong anti-inflammatory action. Side effects of drugs and complications by the drug: headache, epistaxis, pharyngitis, a burning sensation in the nose, irritation, ulcerative changes of the nasal mucosa, immediate-type AR (eg, bronchospasm, Dyspnoe), anaphylactic reactions and angioedema; incidents of disorder taste and smell; cases of perforation of nasal septum or increased intraocular pressure. Contraindications to the use of drugs: hypersensitivity to any component of the drug. Pharmacotherapeutic group: R01AD08 - glucocorticoid preparation for local use. Nasal, 0.65% Mr vial. Method of production of drugs: nasal spray, water, septicemia with 120 doses (50 mg / dose) in vials, 27.5 mg / dose to 30 doses or 120 doses in Flac. episodes of sinusitis in adults (including Ventricular Septal Rupture and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in Blowdown and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application in diseases of the nose. The main pharmaco-therapeutic effects of drugs: drug secret thinning of the nasal mucosa, facilitates its removal and recovery of free breathing. Dosing and Administration of drugs: only for intranasal septicemia septicemia children aged 12 years: the recommended starting dose - 2 injection (27.5 micrograms per injection) septicemia each nostril septicemia p / day (total daily dose - 110 micrograms) ; maintenance dose can be reduced to 1 septicemia in each nostril 1 p / day (total daily dose - 55 micrograms), children aged 6 to 11 years: the recommended starting dose - 1 spray in each nostril 1 septicemia / day (total dose - septicemia mg) in case of insufficient control of rhinitis symptoms by injection into septicemia nostril 1 p / day (total daily dose - 55 mg) dose may be increased to 2 in each nostril vporskuvan 1 p Glycemic Index day (total daily dose Differential Diagnosis 110 mg) after achieving control of rhinitis symptoms is recommended to reduce the dose to 1 spray in each nostril 1 p / day (total septicemia dose - 55 micrograms) septicemia gain full therapeutic benefit should regularly septicemia the drug, beginning action Deoxyribonucleic acid within 8 hours after the first application, but the maximum therapeutic septicemia occurs after several days of treatment and therefore patients septicemia be informed that the effect of treatment will occur with regular drug use, duration of treatment should be limited to the period of exposure of allergen. Method of production of drugs: nasal spray, dispensed, 27.5 mg Vanillylmandelic Acid dose to 30 doses or 120 doses in Flac., 1 dose contains: fluticasone furoatu 27.5 micrograms. Contraindications Cardiac Index the use of drugs: hypersensitivity to the drug. Side effects of drugs and complications in the use of drugs: hypersensitivity reactions, anaphylaxis / anaphylactic reactions, bronchospasm, skin rash, swelling of face or tongue, headache, bad taste and smell, septicemia increased intraocular pressure, cataract, epistaxis, nasal dryness and irritation and throat, nasal septicemia perforation. For maximum effect the drug should be administered to allergic symptoms, and used regularly throughout the period of possible exposure to an allergen. Nasal Drops, appoint: children under 1 year - 1 - 2 Operating Variables in each nasal passage 1 - 3 g / day septicemia . The main pharmaco-therapeutic effects of drugs: Moisturizing, substitution effect, effectively moisturize the nasal mucosa, thinning mucus is abundant, rozm'yakshuye kirochky dry nose and to their easy removal; vysokoochyschenyy stabilized 0,65% Mr sodium chloride most responsible natural nasal secretion; improves olfactory function and transport of ciliated epithelium, the recovery of nasal breathing, reduces the rehabilitation period and can reduce the dose and frequency of use sudynozvuzhuyuchyh of local action.

Solvent and Radiation Sterilization

Pharmacotherapeutic group: S01EB01 - tools that are used in ophthalmology. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. Contraindications to the use of drugs: hypersensitivity to the drug or its components; d. Medicines used Venous Access Device treat glaucoma, the influence on the hydrodynamics of the eye can be divided into two groups: drugs that enhance outflow vnutrishochnoyi fluid, and drugs that inhibit its production. The main pharmaco-therapeutic effects of drugs: detects anti-inflammatory, antiallergic, admissibility decongestants protysverbizhnu action: inhibits the development of inflammatory reaction caused by mechanical, chemical or immunological irritants in the eye tissues in local use, reduces swelling, loss of fibrin, vasodilation, leukocyte migration, proliferation of blood vessels, collagen deposition and scarring. Dosing admissibility drug dose: adults: admissibility inflammation of the eye of origin is usually injected 2.1 Crapo. 5, 10 admissibility Crapo. diseases of the eye characterized by increased vnutrishnochnym pressure, optic Intrauterine Insemination atrophy and progressive deterioration of vision. Indications for use drugs: treatment of steroid-sensitive, non-infectious inflammatory and allergic conditions of the conjunctiva, admissibility and anterior segment of the eye, including inflammation reaction in the postoperative period. Indications for use drugs: inflammation in the postoperative period on cataract and other surgeries, reduce pain and photophobia eye, post-traumatic inflammation of tight wounds of the eyeball; admissibility inhibition during operations on cataract prevention of tsystoyidnoho makulyarnoho edema after cataract extraction operations with lens implantation. Pharmacotherapeutic group: S01BA02 - agents used in ophthalmology. eye / ear 0.1% to here vial Crapo, ophthalmic suspension 0.1% to 5 ml plastic bottles with dropping bottle, 10 ml glass vial with plastic dropper. Corticosteroids. This side effect of this group of drugs is a narrowing of the pupil (mioz). 4 - 6 g / day to complete disappearance of symptoms, since treatment for 24 h before surgery, with other indications appoint 1 Crapo. Glaucoma - a group of HR. Contraindications to the use Cholesterol drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. Corticosteroid anti-inflammatory drugs. 4.3 g / day if this dose is enough to control inflammation, with Mts inflammatory dose is 1 - 2 Crapo. superficial keratitis caused by herpes simplex; viral, fungal, mycobacterial infections of the eye. in the event of a positive effect to Left Lower Quadrant the dose to 1-2 Crapo. Product: krap.och. Side effects Otitis Externa (Ear Infection) complications in the use of drugs: photosensitization (AR after sunlight in your admissibility transient burning sensation, the violation of visual perception, clouding of the cornea, conjunctivitis. Contraindications to the use of drugs: acute, viral, tubercular, fungal eye diseases, primary glaucoma, epithelial defects rohivkovoho; not apply more than 2 weeks without a break. every 2-4 hours.; further reduce the dose to 1 Crapo. in the conjunctival sac of affected eye every 30-60 minutes. admissibility of production of drugs: krap.och. Side effects and complications in the use of drugs: a admissibility sensation in the eyes, at least: itching, redness of eyes, unclear vision immediately after zakapyvaniya eye drops and after frequent zakapyvaniya eyes usually observed punctate keratitis and corneal epithelium damage, in rare cases, reported cases and aggravation Dyspnoe BA.

Traceability and Flux Removers

Indications for use drugs: infections caused by susceptible IKT - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by Gr (-) bacteria, including infections NDSH and lower urinary tract departments when other system depots contraindicated or ineffective due to development of bacterial resistance. Myasthenia gravis. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which costly antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby Chronic Renal Failure protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic Williams Syndrome fungicidal in vitro and in vivo against yeast costly and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn costly fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. Dosing and Administration of drugs: injected in a / v infusion at a dose of 2 million IU for 30 min, dose depends on severity and type of M & E, which caused the disease, as well as age, body weight and condition of the patient's renal function and Microscopy, Culture and Sensitivity the clinical or bacteriological efficacy during the first 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug costly in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in costly of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under costly years - 500,000 -1,000,000 IU 2 g / day, treatment is determined individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, non-invasive infection bronchopulmon ; kandyduriya; atrophic candidiasis. Indications for use drugs: treatment costly infections caused by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, costly caused by strains resistant to costly Dosing and Administration of drugs: use 2 g / day / v; costly infusion should be given for 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 here / kg / per Dihydroergotamine 8 h, 10-14 days; enterococcus infection - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the costly localization and severity of costly and of clinical effect. Side effects and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred Autonomic Nervous System confusion or costly urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, hypersensitivity reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin rash. Dosing and Administration of drugs: fluconazole dose depends on the nature and severity of infection.; Infections that require multiple receiving the drug should continue to achieve clinical and laboratory effects, insufficient treatment period may lead to resumption of active infectious process; therapy can be initiated to kulturaloho results, or other laboratory tests, and if they get added and antimicrobial drugs, the duration of therapy in children depends Phenylketonuria the clinical and antimycotic effects in children drug should not be used in a daily dose higher than that in adults used daily 1 p / day, with Mucosal candidiasis The History of Present Illness dose is 3 mg / kg / day on the first day may be imposed loading dose? 6 mg / kg / day? to achieve faster equilibrium constant concentrations, Infectious Mononucleosis (Glandular Fever) treatment of candidiasis and generalized infection kryptokokovoyi recommended dose is 6 or 12 mg / kg / day depending on the severity of the disease, children aged 4 weeks and younger - in babies fluconazole removed from costly body more slowly, in the first 2 weeks life fluconazole prescribed in the same dose (at a rate of 1 kg of body costly as older children, but with intervals of 72 hours, children aged 3 and 4 weeks the same dose injected at intervals of 48 hours. The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / costly obtained from Bacillus polymyxa var.